CCChun Chou

Chun Chou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chun Chou has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Briana G. Nixon

    Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA

    2 shared publications
  • Jing Zhang

    Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA

    2 shared publications
  • Kristelle J. Capistrano

    Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA

    2 shared publications
  • Ming O. Li

    Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    2 shared publications
  • Mytrang H. Do

    Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA

    2 shared publications
  • Shun Li

    Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA

    2 shared publications

Latest Publications

  • Top Cited Papers

    Reprogramming tumour-associated macrophages to outcompete cancer cells

    by Xian Zhang, Shun Li, Isha Malik, Mytrang H. Do, Liangliang Ji, Chun Chou, Wei Shi, Kristelle J. Capistrano, Jing Zhang, Ting-Wei Hsu, et al.

    In metazoan organisms, cell competition acts as a quality control mechanism to eliminate unfit cells in favour of their more robust neighbours1,2. This mechanism has the potential to be maladapted, promoting the selection of aggressive cancer cells3,4,5,6. Tumours are metabolically active and are populated by stroma cells7,8, but how environmental factors affect cancer cell competition remains largely unknown. Here we show that tumour-associated macrophages (TAMs) can be dietarily or genetically reprogrammed to outcompete MYC-overexpressing cancer cells. In a mouse model of breast cancer, MYC overexpression resulted in an mTORC1-dependent ‘winner’ cancer cell state. A low-protein diet inhibited mTORC1 signalling in cancer cells and reduced tumour growth, owing unexpectedly to activation of the transcription factors TFEB and TFE3 and mTORC1 in TAMs. Diet-derived cytosolic amino acids are sensed by Rag GTPases through the GTPase-activating proteins GATOR1 and FLCN to control Rag GTPase effectors including TFEB and TFE39,10,11,12,13,14. Depletion of GATOR1 in TAMs suppressed the activation of TFEB, TFE3 and mTORC1 under the low-protein diet condition, causing accelerated tumour growth; conversely, depletion of FLCN or Rag GTPases in TAMs activated TFEB, TFE3 and mTORC1 under the normal protein diet condition, causing decelerated tumour growth. Furthermore, mTORC1 hyperactivation in TAMs and cancer cells and their competitive fitness were dependent on the endolysosomal engulfment regulator PIKfyve. Thus, noncanonical engulfment-mediated Rag GTPase-independent mTORC1 signalling in TAMs controls competition between TAMs and cancer cells, which defines a novel innate immune tumour suppression pathway that could be targeted for cancer therapy.


  • Programme of self-reactive innate-like T cell-mediated cancer immunity

    by Chun Chou, Xian Zhang, Chirag Krishna, Briana G. Nixon, Saida Dadi, Kristelle J. Capistrano, Emily R. Kansler, Miranda Steele, Jian Han, Amy Shyu, et al.

    Cellular transformation induces phenotypically diverse populations of tumour-infiltrating T cells1,2,3,4,5, and immune checkpoint blockade therapies preferentially target T cells that recognize cancer cell neoantigens6,7. Yet, how other classes of tumour-infiltrating T cells contribute to cancer immunosurveillance remains elusive. Here, in a survey of T cells in mouse and human malignancies, we identified a population of αβ T cell receptor (TCR)-positive FCER1G-expressing innate-like T cells with high cytotoxic potential8 (ILTCKs). These cells were broadly reactive to unmutated self-antigens, arose from distinct thymic progenitors following early encounter with cognate antigens, and were continuously replenished by thymic progenitors during tumour progression. Notably, expansion and effector differentiation of intratumoural ILTCKs depended on interleukin-15 (IL-15) expression in cancer cells, and inducible activation of IL-15 signalling in adoptively transferred ILTCK progenitors suppressed tumour growth. Thus, the antigen receptor self-reactivity, unique ontogeny, and distinct cancer cell-sensing mechanism distinguish ILTCKs from conventional cytotoxic T cells, and define a new class of tumour-elicited immune response.


  • Open Access

    Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes

    by Elena Tonc, Yoshiko Takeuchi, Chun Chou, Yu Xia, Melanie Holmgren, Chika Fujii, Saravanan Raju, Gue Su Chang, Masahiro Iwamoto, Takeshi Egawa

    The proliferative burst of B lymphocytes is essential for antigen receptor repertoire diversification during the development and selective expansion of antigen-specific clones during immune responses. High proliferative activity inevitably promotes oncogenesis, the risk of which is further elevated in B lymphocytes by endogenous gene rearrangement and somatic mutations. However, B-cell–derived cancers are rare, perhaps owing to putative intrinsic tumor-suppressive mechanisms. We show that c-MYC facilitates B-cell proliferation as a protumorigenic driver and unexpectedly coengages counteracting tumor suppression through its downstream factor TFAP4. TFAP4 is mutated in human lymphoid malignancies, particularly in >10% of Burkitt lymphomas, and reduced TFAP4 expression was associated with poor survival of patients with MYC-high B-cell acute lymphoblastic leukemia. In mice, insufficient TFAP4 expression accelerated c-MYC–driven transformation of B cells. Mechanistically, c-MYC suppresses the stemness of developing B cells by inducing TFAP4 and restricting self-renewal of proliferating B cells. Thus, the pursuant transcription factor cascade functions as a tumor suppressor module that safeguards against the transformation of developing B cells.


  • Open Access

    c-Myc-induced transcription factor AP4 is required for host protection mediated by CD8+ T cells

    by Chun Chou, Amelia K Pinto, Jonathan D Curtis, Stephen P Persaud, Marina Cella, Chih-Chung Lin, Brian T Edelson, Paul M Allen, Marco Colonna, Erika L Pearce, et al.

    The transcription factor c-Myc is essential for T cell proliferation after priming; however, its expression is transient. Egawa and colleagues show that the transcription factor AP4 is induced by c-Myc and sustains the activation of CD8+ T cells. Although the transcription factor c-Myc is essential for the establishment of a metabolically active and proliferative state in T cells after priming, its expression is transient. It remains unknown how T cell activation is maintained after c-Myc expression is downregulated. Here we identified AP4 as the transcription factor that was induced by c-Myc and sustained activation of antigen-specific CD8+ T cells. Despite normal priming, AP4-deficient CD8+ T cells failed to continue transcription of a broad range of c-Myc-dependent targets. Mice lacking AP4 specifically in CD8+ T cells showed enhanced susceptibility to infection with West Nile virus. Genome-wide analysis suggested that many activation-induced genes encoding molecules involved in metabolism were shared targets of c-Myc and AP4. Thus, AP4 maintains c-Myc-initiated cellular activation programs in CD8+ T cells to control microbial infection.